Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path

Patent Law Concept 3D Illustration

Related Content

Humira Biosimilar Settlement Could Be Model For Other Disputes

Sep 29 2017

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Sep 21 2017

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Aug 01 2017

Related Companies

AbbVie Inc.

Amgen, Inc.

Boehringer Ingelheim GmbH

Pfizer Inc.

Johnson & Johnson

Express Scripts Holding Company

Additional Topics

Biosimilars Intellectual Property Launches Commercial BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window